Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 4/20 | 0.52 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 6/20 | 0.40 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.39 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18631597 | 0.98 | GRM1 (0.50) | GRM1GRM5GRM2GRM4DPP4 | |
| Hydrochloric Acid SCHEMBL18631596 | 0.95 | GRM1 (0.48) | GRM1GRM5GRM2GRM4DPP4 | |
| SCHEMBL6739912 | 0.91 | DPP4 (0.49) | GRM1DPP4ALDH1A1ALOX15FAP | |
| SCHEMBL255570 | 0.91 | DPP4 (0.49) | GRM1DPP4ALDH1A1ALOX15FAP | |
| SCHEMBL23460047 | 0.91 | DPP4 (0.49) | GRM1DPP4ALDH1A1ALOX15FAP | |
| Hydrochloric Acid SCHEMBL28561376 | 0.89 | ALDH1A1 (0.50) | GRM1DPP4ALDH1A1ALOX15FAP | |
| Hydrochloric Acid SCHEMBL28561377 | 0.89 | ALDH1A1 (0.50) | GRM1DPP4ALDH1A1ALOX15FAP | |
| SCHEMBL5988117 | 0.82 | GRM1 (0.45) | GRM1GRM5GRM2GRM4DPP4 | |
| SCHEMBL13334525 | 0.82 | DPP4 (0.59) | GRM1DPP4FAPPITRM1DPP8 | |
| Hydrochloric Acid SCHEMBL5987774 | 0.81 | GRM1 (0.44) | GRM1GRM5GRM2GRM4DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-3114107-B1 | PROPELLANE DERIVATES AND SYNTHESIS | RECURIUM IP HOLDINGS LLC (US) | 2020-07-22 | — | — | EP | disclosed |
| US-10654812-B2 | Propellane derivates and synthesis | RECURIUM IP HOLDINGS LLC (US) | 2020-05-19 | — | — | US | disclosed |
| US-20170081295-A1 | PROPELLANE DERIVATES AND SYNTHESIS | RECURIUM IP HOLDINGS, LLC | 2017-03-23 | — | — | US | disclosed |
| US-20170081295-A1 | PROPELLANE DERIVATES AND SYNTHESIS | RECURIUM IP HOLDINGS, LLC | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170081295-A1 | PROPELLANE DERIVATES AND SYNTHESIS | PDHA1, PDHA2, DHPS | GRM1 407/4885GRM5 1253/4885GRM2 1638/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | GRM1 1780/4885GRM5 2516/4885GRM2 2853/4885 |
| US-10654812-B2 | Propellane derivates and synthesis | PDHA1, PDHA2, DHPS | GRM1 407/4885GRM5 1253/4885GRM2 1638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.